Endocrine Society GUIDELINES Bundle (free trial)

Osteoporosis

Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1140214

Contents of this Issue

Navigation

Page 1 of 7

➤ Treat high risk individuals - particularly those with previous fracture. ➤ Consider bisphosphonates as the first line therapeutic choice for postmenopausal women at high risk of fracture. ➤ Reassess fracture risk after patient has been on bisphosphonates for 3-5 years. ➤ Following reassessment, prescribe a "bisphosphonate holiday" for women who are on bisphosphonates and are low-to-moderate risk of fracture. ➤ Consider anabolic therapy (teriparatide or abaloparatide) for women at very high risk of fractures, including those with multiple fractures. ➤ All women undergoing treatment with osteoporosis therapies other than anabolic therapy should consume calcium and vitamin D in their diet or via supplements. ➤ Monitor the BMD of high-risk individuals with a low BMD every 1 to 3 years. Key Points

Articles in this issue

Archives of this issue

view archives of Endocrine Society GUIDELINES Bundle (free trial) - Osteoporosis